These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 27113353)

  • 21. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
    Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
    Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
    Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
    Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
    [No Abstract]   [Full Text] [Related]  

  • 27. Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma.
    Sheehan WJ; Krouse RZ; Calatroni A; Gergen PJ; Gern JE; Gill MA; Gruchalla RS; Khurana Hershey GK; Kattan M; Kercsmar CM; Lamm CI; Little FF; Makhija MM; Searing DA; Zoratti E; Busse WW; Teach SJ;
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3021-3028.e2. PubMed ID: 32376491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
    Assayag M; Moshel S; Kohan M; Berkman N
    Allergy Asthma Proc; 2018 Jan; 39(1):36-42. PubMed ID: 29279058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
    Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
    Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum eosinophil-derived neurotoxin: correlation with persistent airflow limitation in adults with house-dust mite allergic asthma.
    Gon Y; Ito R; Hattori T; Hiranuma H; Kumasawa F; Kozu Y; Endo D; Koyama D; Shintani Y; Eriko T; Soda K; Maruoka S; Hashimoto S
    Allergy Asthma Proc; 2015; 36(6):e113-20. PubMed ID: 26534742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
    Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
    Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
    Sarinho E; Cruz AA
    J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S127-32. PubMed ID: 17136288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
    Johansson SGO; Lilja G; Hallberg J; Nopp A
    Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does anti-IgE therapy help in asthma? Efficacy and controversies.
    Avila PC
    Annu Rev Med; 2007; 58():185-203. PubMed ID: 17059361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.